explore -WSS

explore

author：fashion 2025-09-03 03:39:00 - browse：731

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

WSS

Second House panel advances two

Second House panel advances two

Choosing scientific sides in the fight against Alzheimer's

Arc Institute generative AI designs new CRISPR systems

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Solving academic medical centers' existential crisis

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Drug repurposing or repositioning? The language matters

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Walensky prepares to leave CDC — and Congress — behind

Hospitals use virtual reality to design more inclusive rooms for kids

ChatGPT in medicine: STAT answers readers' burning questions

Case highlights the risks of experimental stem cell therapy

Medical records are filled with copy

Choosing scientific sides in the fight against Alzheimer's

Peter Hotez and the public health issue of online harassment

Astronauts get first look at the spacecraft that will fly them around the moon

focus

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Wearables generate powerful data but its not useful to doctors, yet

Biden praises World Series champion Astros for impact off the field during White House celebration

‘The Bear’ and hospitality in hospitals

Choosing scientific sides in the fight against Alzheimer's

Arc Institute generative AI designs new CRISPR systems

entertainment

entertainment

explore

knowledge